Appln. No. 10/734,155 Amd. dated February 13, 2006 Reply to Office Action of November 14, 2005

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Currently Amended) A method for inhibiting the calcium cascade <u>comprising</u> consisting of administering to an animal in need thereof an effective amount of at least one <u>pharmaceutically acceptable polyvalent</u> metal ion that blocks the calcium cascade.
- 2. (Original) The method according to claim 1 wherein the metal ions are selected from the group consisting of zinc, copper, magnesium, manganese, iron, and aluminum, and mixtures thereof.
- 3. (Original) The method according to claim 1 wherein the animal is suffering from an autoimmune disease which causes secretions and eruptions via the Calcium cascade.
- 4. (Withdrawn) The method according to claim 1 wherein the animal is suffering from rhinitis.
- 5. (Withdrawn) The method according to claim 1 wherein the animal is suffering from herpes virus infection.
- 6. (Original) The method according to claim 1 wherein the metal ions are administered through the mouth to the nasal cavity.

Appln. No. 10/734,155 Amd. dated February 13, 2006 Reply to Office Action of November 14, 2005

- 7. (Original) The method according to claim 6 wherein the metal ions are in a composition which has a pH of about 4.8 so that the metal ions are delivered across the mucous membranes of the mouth into the nasal cavity.
- 8. (Original) The method according to claim 7 wherein the composition contains an amino acid as a buffer.
- 9. (Original) The method according to claim 8 wherein the amino acid is glycine.
- 10. (Original) The method according to claim 9 wherein the metal ion is zinc.
- 11. (Original) The method according to claim 10 wherein the metal ions are copper and zinc.
  - 12. (Cancelled)
- 13. (Withdrawn) A method for inhibiting the formation of histamine by blocking the calcium cascade comprising administering to a patient in need thereof and effective amount of at least one metal ion that blocks the calcium cascade.
- 14. (New) The method according to claim 1 wherein the metal ion is in a dosage form for delivering a therapeutically effective amount of the metal ion from one anatomical compartment to a contiguous anatomical compartment, said dosage form being designed by the steps of:

- (a) selecting a recipient compartment of the human body for delivery of the metal ion, and selecting a contiguous repository compartment of the human body for placement of the dosage form;
- (b) determining the pH of both the repository and recipient human body compartments;
- (c) selecting a therapeutically effective amount of the metal ion to be used in treatment of the recipient compartment;
- (d) wherein the pH of the repository compartment necessary to allow an effective amount of the drug according to the formula:

 $-pH_{(repository)} = log[repository] = \frac{NAX}{(T)(2.30R_t)} + log[recipient]$ 

pH=pH of the repository compartment with the dosage form in place,

N=the average Newtonian viscosity of the compartments' fluids,

X=the distance the drug is to travel,

A=the surface area of the repository compartment,

T=the transport time selected,

R=the universal gas constant 1.987 cal/mole-degree or 8.314 joule/mole, and

log is the logarithm of the concentration of drug in

Appln. No. 10/734,155 Amd. dated February 13, 2006 Reply to Office Action of November 14, 2005

the repository compartment,

log is the logarithm of the concentration of drug in the recipient compartment,

t=temperature of the body compartment in absolute degrees--normally 310 degrees Kelvin; selecting a buffering system that will provide sufficient buffering effect in the repository compartment to provide delivery of a therapeutic amount of the metal ion to the recipient compartment by producing a pH difference between the repository and recipient compartments, wherein said buffering system is capable of sustaining the pH difference in the repository compartment for a period of time sufficient for delivery of the metal ion to the recipient compartment;

(e) admixing the therapeutically effective amount of the metal ion together with the components of the selected buffering system, a pharmaceutically appropriate base and inert ingredients, into a desired dosage form.